Wedbush reissued their neutral rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a report released on Thursday morning,RTT News reports. They currently have a $9.00 price objective on the stock. Wedbush also issued estimates for Arvinas’ Q1 2026 earnings at ($0.63) EPS and Q2 2026 earnings at ($0.65) EPS. ARVN has been the […]

Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “neutral” rating reiterated by stock analysts at Wedbush in a research note issued to investors on Friday,RTT News reports. They presently have a $2.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 145.01% from the company’s current price. A […]